<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23097443</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.</ArticleTitle><Pagination><StartPage>611</StartPage><EndPage>620</EndPage><MedlinePgn>611-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02226-12</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV-71) infections are usually associated with mild hand, foot, and mouth disease in young children but have been reported to cause severe neurological complications with high mortality rates. To date, four EV-71 receptors have been identified, but inhibition of these receptors by antagonists did not completely abolish EV-71 infection, implying that there is an as yet undiscovered receptor(s). Since EV-71 has a wide range of tissue tropisms, we hypothesize that EV-71 infections may be facilitated by using receptors that are widely expressed in all cell types, such as heparan sulfate. In this study, heparin, polysulfated dextran sulfate, and suramin were found to significantly prevent EV-71 infection. Heparin inhibited infection by all the EV-71 strains tested, including those with a single-passage history. Neutralization of the cell surface anionic charge by polycationic poly-d-lysine and blockage of heparan sulfate by an anti-heparan sulfate peptide also inhibited EV-71 infection. Interference with heparan sulfate biosynthesis either by sodium chlorate treatment or through transient knockdown of N-deacetylase/N-sulfotransferase-1 and exostosin-1 expression reduced EV-71 infection in RD cells. Enzymatic removal of cell surface heparan sulfate by heparinase I/II/III inhibited EV-71 infection. Furthermore, the level of EV-71 attachment to CHO cell lines that are variably deficient in cell surface glycosaminoglycans was significantly lower than that to wild-type CHO cells. Direct binding of EV-71 particles to heparin-Sepharose columns under physiological salt conditions was demonstrated. We conclude that EV-71 infection requires initial binding to heparan sulfate as an attachment receptor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Chee Wah</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, University Malaya, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poh</LastName><ForeName>Chit Laa</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Sam</LastName><ForeName>I-Ching</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Yoke Fun</ForeName><Initials>YF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006025">Glycosaminoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006025" MajorTopicYN="N">Glycosaminoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="Y">Virus Attachment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23097443</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pii">JVI.02226-12</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown BA, Pallansch MA. 1995. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 39:195&#x2013;205</Citation><ArticleIdList><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam IC, Wee KL, AbuBakar S. 2011. Enterovirus 71 in Malaysia: a decade later. Neurol. Asia 16:1&#x2013;15</Citation></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 9:1097&#x2013;1105</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10:778&#x2013;790</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Haywood AM. 1994. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J. Virol. 68:1&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236257</ArticleId><ArticleId IdType="pubmed">8254718</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 15:794&#x2013;797</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. 2012. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J. Virol. 86:5686&#x2013;5696</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Koike S. 2011. Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. J. Virol. 85:4937&#x2013;4946</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126200</ArticleId><ArticleId IdType="pubmed">21389126</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat. Med. 15:798&#x2013;801</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>
Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF.
2012. 
Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol.
12:162
doi:10.1186/1471-2180-12-162</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-12-162</ArticleId><ArticleId IdType="pmc">PMC3478995</ArticleId><ArticleId IdType="pubmed">22853823</ArticleId></ArticleIdList></Reference><Reference><Citation>
Yang B, Chuang H, Yang KD.
2009. 
Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol. J.
6:141
doi:10.1186/1743-422X-6-141</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, Ho MS. 2011. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J. Virol. 85:11809&#x2013;11820</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Ng MM, Chu JJ. 2010. Developments towards antiviral therapies against enterovirus 71. Drug Discov. Today 15:1041&#x2013;1051</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tan CW, Chan YF, Sim KM, Tan EL, Poh CL.
2012. 
Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. PLoS One
7:e34589
doi:10.1371/journal.pone.0034589</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034589</ArticleId><ArticleId IdType="pmc">PMC3341398</ArticleId><ArticleId IdType="pubmed">22563456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chu C, Chiu CH. 2002. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect. Dis. 186:1161&#x2013;1164</Citation><ArticleIdList><ArticleId IdType="pubmed">12355368</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh TM. 2005. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 67:31&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">15916817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar HR, Poh CL, Fecondo J, Grollo L. 2012. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against enterovirus 71. Virus Res. 169:22&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Honke K, Taniguchi N. 2002. Sulfotransferases and sulfated oligosaccharides. Med. Res. Rev. 22:637&#x2013;654</Citation><ArticleIdList><ArticleId IdType="pubmed">12369092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. 1998. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">9631661</ArticleId></ArticleIdList></Reference><Reference><Citation>Laquerre S, Argnani R, Anderson DB, Zucchini S, Manservigi R, Glorioso JC. 1998. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J. Virol. 72:6119&#x2013;6130</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110418</ArticleId><ArticleId IdType="pubmed">9621076</ArticleId></ArticleIdList></Reference><Reference><Citation>WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63:52&#x2013;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247656</ArticleId><ArticleId IdType="pubmed">2535752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondor I, Ugolini S, Sattentau QJ. 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 72:3623&#x2013;3634</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109583</ArticleId><ArticleId IdType="pubmed">9557643</ArticleId></ArticleIdList></Reference><Reference><Citation>Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, Norcross MA. 1995. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J. Virol. 69:2233&#x2013;2239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188892</ArticleId><ArticleId IdType="pubmed">7884870</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866&#x2013;871</Citation><ArticleIdList><ArticleId IdType="pubmed">9256277</ArticleId></ArticleIdList></Reference><Reference><Citation>Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565&#x2013;1570</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114064</ArticleId><ArticleId IdType="pubmed">11152531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CS, Hsiao JC, Chang YS, Chang W. 1998. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J. Virol. 72:1577&#x2013;1585</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124638</ArticleId><ArticleId IdType="pubmed">9445060</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddi HV, Lipton HL. 2002. Heparan sulfate mediates infection of high-neurovirulence Theiler's viruses. J. Virol. 76:8400&#x2013;8407</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155119</ArticleId><ArticleId IdType="pubmed">12134043</ArticleId></ArticleIdList></Reference><Reference><Citation>Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. 2001. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75:8772&#x2013;8780</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115122</ArticleId><ArticleId IdType="pubmed">11507222</ArticleId></ArticleIdList></Reference><Reference><Citation>Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438&#x2013;1445</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124624</ArticleId><ArticleId IdType="pubmed">9445046</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze A, Gripon P, Urban S. 2007. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46:1759&#x2013;1768</Citation><ArticleIdList><ArticleId IdType="pubmed">18046710</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:41003&#x2013;41012</Citation><ArticleIdList><ArticleId IdType="pubmed">12867431</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrnes AP, Griffin DE. 1998. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72:7349&#x2013;7356</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109959</ArticleId><ArticleId IdType="pubmed">9696831</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow IG, Sioofy AB, Powell RM, Evans DJ. 2001. Echoviruses bind heparan sulfate at the cell surface. J. Virol. 75:4918&#x2013;4921</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114248</ArticleId><ArticleId IdType="pubmed">11312365</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish NJ, Williams CH, Kaloudas D, Roivainen M, Stanway G. 2012. Symmetry-related clustering of positive charges is a common mechanism for heparan sulfate binding in enteroviruses. J. Virol. 86:11163&#x2013;11170</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457184</ArticleId><ArticleId IdType="pubmed">22855495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner AE, Jahn B, Hammerschmidt E, Wutzler P, Schmidtke M. 2006. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J. Virol. 80:6629&#x2013;6636</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1488958</ArticleId><ArticleId IdType="pubmed">16775350</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood LJ, Gerber H, Sobrino F, Summerfield A, McCullough KC. 2008. Dendritic cell internalization of foot-and-mouth disease virus: influence of heparan sulfate binding on virus uptake and induction of the immune response. J. Virol. 82:6379&#x2013;6394</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447102</ArticleId><ArticleId IdType="pubmed">18448534</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson T, Ellard FM, Ghazaleh RA, Brookes SM, Blakemore WE, Corteyn AH, Stuart DI, Newman JW, King AM. 1996. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:5282&#x2013;5287</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190485</ArticleId><ArticleId IdType="pubmed">8764038</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari V, Liu J, Valyi-Nagy T, Shukla D. 2011. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J. Biol. Chem. 286:25406&#x2013;25415</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137111</ArticleId><ArticleId IdType="pubmed">21596749</ArticleId></ArticleIdList></Reference><Reference><Citation>
Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG.
2012. 
Crystal structure of human enterovirus 71. Science
336:1274
doi:10.1126/science.1218713</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Guex N, Peitsch MC. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714&#x2013;2723</Citation><ArticleIdList><ArticleId IdType="pubmed">9504803</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam IC, AbuBakar S. 2010. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect. Genet. Evol. 10:404&#x2013;412</Citation><ArticleIdList><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Guibinga GH, Miyanohara A, Esko JD, Friedmann T. 2002. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol. Ther. 5:538&#x2013;546</Citation><ArticleIdList><ArticleId IdType="pubmed">11991744</ArticleId></ArticleIdList></Reference><Reference><Citation>Presto J, Thuveson M, Carlsson P, Busse M, Wilen M, Eriksson I, Kusche-Gullberg M, Kjellen L. 2008. Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation. Proc. Natl. Acad. Sci. U. S. A. 105:4751&#x2013;4756</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290785</ArticleId><ArticleId IdType="pubmed">18337501</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlasak M, Goesler I, Blaas D. 2005. Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment. J. Virol. 79:5963&#x2013;5970</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1091682</ArticleId><ArticleId IdType="pubmed">15857982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S, Massague J, Lindahl U, Esko JD. 1992. A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 89:2267&#x2013;2271</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48638</ArticleId><ArticleId IdType="pubmed">1532254</ArticleId></ArticleIdList></Reference><Reference><Citation>Esko JD, Stewart TE, Taylor WH. 1985. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 82:3197&#x2013;3201</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397742</ArticleId><ArticleId IdType="pubmed">3858816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain KM, Leong KL, Ng MM, Chu JJ. 2011. The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. J. Biol. Chem. 286:309&#x2013;321</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012988</ArticleId><ArticleId IdType="pubmed">20956521</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, Shao HY, Liu CC, Sia C, Chong P, Chow YH.
2012. 
Human SCARB2-mediated entry and endocytosis of EV71. PLoS One
7:e30507
doi:10.1371/journal.pone.0030507</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030507</ArticleId><ArticleId IdType="pmc">PMC3260287</ArticleId><ArticleId IdType="pubmed">22272359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgard P, Stockert R. 2000. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 32:1069&#x2013;1077</Citation><ArticleIdList><ArticleId IdType="pubmed">11050058</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry EE, Lea SM, Jackson T, Newman JW, Ellard FM, Blakemore WE, Abu-Ghazaleh R, Samuel A, King AM, Stuart DI. 1999. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J. 18:543&#x2013;554</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171147</ArticleId><ArticleId IdType="pubmed">9927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X, Dong W, Wan X, Huang N, Shen X, Liang Z, Li W. 2012. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B2. J. Biol. Chem. 287:6406&#x2013;6420</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Delputte PL, Vanderheijden N, Nauwynck HJ, Pensaert MB. 2002. Involvement of the matrix protein in attachment of porcine reproductive and respiratory syndrome virus to a heparin like receptor on porcine alveolar macrophages. J. Virol. 76:4312&#x2013;4320</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155060</ArticleId><ArticleId IdType="pubmed">11932397</ArticleId></ArticleIdList></Reference><Reference><Citation>Misinzo G, Delputte PL, Meerts P, Lefebvre DJ, Nauwynck HJ. 2006. Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors for its attachment to host cells. J. Virol. 80:3487&#x2013;3494</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1440380</ArticleId><ArticleId IdType="pubmed">16537616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Zaia J. 2009. Organ-specific heparan sulfate structural phenotypes. J. Biol. Chem. 284:11806&#x2013;11814</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673249</ArticleId><ArticleId IdType="pubmed">19244235</ArticleId></ArticleIdList></Reference><Reference><Citation>Escarmis C, Carrillo EC, Ferrer M, Arriaza JF, Lopez N, Tami C, Verdaguer N, Domingo E, Franze-Fernandez MT. 1998. Rapid selection in modified BHK-21 cells of a foot-and-mouth disease virus variant showing alterations in cell tropism. J. Virol. 72:10171&#x2013;10179</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110560</ArticleId><ArticleId IdType="pubmed">9811758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:5115&#x2013;5123</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191746</ArticleId><ArticleId IdType="pubmed">9188578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78:8271&#x2013;8280</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446099</ArticleId><ArticleId IdType="pubmed">15254199</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimstra WB, Ryman KD, Johnston RE. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol. 72:7357&#x2013;7366</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109960</ArticleId><ArticleId IdType="pubmed">9696832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Lobigs M. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J. Virol. 76:4901&#x2013;4911</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136177</ArticleId><ArticleId IdType="pubmed">11967307</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddi HV, Kumar AS, Kung AY, Kallio PD, Schlitt BP, Lipton HL. 2004. Heparan sulfate-independent infection attenuates high-neurovirulence GDVII virus-induced encephalitis. J. Virol. 78:8909&#x2013;8916</Citation><ArticleIdList><ArticleId IdType="pmc">PMC479051</ArticleId><ArticleId IdType="pubmed">15280499</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 19:424&#x2013;429</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>